Lyell Immunopharma Presents New Data on Ronde-cel at ASH Meeting

TradingView
2025.12.08 11:23
portai
I'm PortAI, I can summarize articles.

On December 7, 2025, Lyell Immunopharma presented new data on ronde-cel at the ASH Annual Meeting. Key Highlights: Ronde-cel showed a 93% response rate in 3L+ LBCL patients.83% response rate observed in 2L LBCL patients.Manageable safety profile with no severe CRS cases.Ronde-cel demonstrated robust CAR T-cell expansion.Original SEC Filing: Lyell Immunopharma, Inc. [ LYEL ] - 8-K - Dec. 08, 2025DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

On December 7, 2025, Lyell Immunopharma presented new data on ronde-cel at the ASH Annual Meeting.

Key Highlights:

  • Ronde-cel showed a 93% response rate in 3L+ LBCL patients.
  • 83% response rate observed in 2L LBCL patients.
  • Manageable safety profile with no severe CRS cases.
  • Ronde-cel demonstrated robust CAR T-cell expansion.

Original SEC Filing: Lyell Immunopharma, Inc. [ LYEL ] - 8-K - Dec. 08, 2025

Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer